These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1038 related items for PubMed ID: 15751769

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Initial experience with oral valganciclovir for pre-emptive cytomegalovirus therapy after lung transplantation.
    Aigner C, Jaksch P, Winkler G, Czebe K, Taghavi S, Marta G, Klepetko W.
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):480-4. PubMed ID: 16091875
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Valganciclovir as pre-emptive therapy for cytomegalovirus infection in allogeneic haematopoietic stem cell transplant recipients.
    Ruiz-Camps I, Len O, de la Cámara R, Gurguí M, Martino R, Jarque I, Barrenetxea C, Díaz de Heredia C, Batlle M, Rovira M, de la Torre J, Torres A, Aguilar M, Espigado I, Martín-Dávila P, Bou G, Borrell N, Aguado JM, Pahissa A, Spanish Network for Research on Infection in Transplantation (RESITRA/REIPI). Spain.
    Antivir Ther; 2011 Jul; 16(7):951-7. PubMed ID: 22024510
    [Abstract] [Full Text] [Related]

  • 8. Does valganciclovir hydrochloride (valcyte) provide effective prophylaxis against cytomegalovirus infection in liver transplant recipients?
    Jain A, Orloff M, Kashyap R, Lansing K, Betts R, Mohanka R, Menegus M, Ryan C, Bozorgzadeh A.
    Transplant Proc; 2005 Sep; 37(7):3182-6. PubMed ID: 16213344
    [Abstract] [Full Text] [Related]

  • 9. Pre-emptive therapy of CMVpp65 antigen positive renal transplant recipients with oral ganciclovir: a randomized, comparative study.
    Sagedal S, Nordal KP, Hartmann A, Midtvedt K, Foss A, Asberg A, Degré M, Fauchald P, Rollag H.
    Nephrol Dial Transplant; 2003 Sep; 18(9):1899-908. PubMed ID: 12937241
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
    Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M, VIPP Study Group.
    Transplantation; 2012 Jan 15; 93(1):61-8. PubMed ID: 22094954
    [Abstract] [Full Text] [Related]

  • 12. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation.
    Devyatko E, Zuckermann A, Ruzicka M, Bohdjalian A, Wieselthaler G, Rödler S, Wolner E, Grimm M.
    J Heart Lung Transplant; 2004 Nov 15; 23(11):1277-82. PubMed ID: 15539126
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of valganciclovir in the treatment of cytomegalovirus disease in kidney and pancreas transplant recipients.
    Luan FL, Chopra P, Park J, Norman S, Cibrik D, Ojo A.
    Transplant Proc; 2006 Dec 15; 38(10):3673-5. PubMed ID: 17175363
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 16. Intragraft cytomegalovirus infection: a randomized trial of valacyclovir prophylaxis versus pre-emptive therapy in renal transplant recipients.
    Reischig T, Nemcová J, Vanecek T, Jindra P, Hes O, Bouda M, Treska V.
    Antivir Ther; 2010 Jan 27; 15(1):23-30. PubMed ID: 20167988
    [Abstract] [Full Text] [Related]

  • 17. Variable viral clearance despite adequate ganciclovir plasma levels during valganciclovir treatment for cytomegalovirus disease in D+/R- transplant recipients.
    Perrottet N, Manuel O, Lamoth F, Venetz JP, Sahli R, Decosterd LA, Buclin T, Pascual M, Meylan P.
    BMC Infect Dis; 2010 Jan 06; 10():2. PubMed ID: 20053269
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.
    Mengelle C, Rostaing L, Weclawiak H, Rossignol C, Kamar N, Izopet J.
    J Med Virol; 2015 May 06; 87(5):836-44. PubMed ID: 25655981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 52.